全文获取类型
收费全文 | 10901篇 |
免费 | 667篇 |
国内免费 | 58篇 |
专业分类
耳鼻咽喉 | 103篇 |
儿科学 | 291篇 |
妇产科学 | 134篇 |
基础医学 | 1600篇 |
口腔科学 | 641篇 |
临床医学 | 884篇 |
内科学 | 2521篇 |
皮肤病学 | 335篇 |
神经病学 | 904篇 |
特种医学 | 291篇 |
外科学 | 1503篇 |
综合类 | 49篇 |
一般理论 | 3篇 |
预防医学 | 863篇 |
眼科学 | 238篇 |
药学 | 638篇 |
中国医学 | 37篇 |
肿瘤学 | 591篇 |
出版年
2024年 | 15篇 |
2023年 | 140篇 |
2022年 | 271篇 |
2021年 | 475篇 |
2020年 | 288篇 |
2019年 | 415篇 |
2018年 | 433篇 |
2017年 | 302篇 |
2016年 | 322篇 |
2015年 | 406篇 |
2014年 | 512篇 |
2013年 | 584篇 |
2012年 | 988篇 |
2011年 | 981篇 |
2010年 | 463篇 |
2009年 | 429篇 |
2008年 | 629篇 |
2007年 | 606篇 |
2006年 | 586篇 |
2005年 | 524篇 |
2004年 | 431篇 |
2003年 | 391篇 |
2002年 | 351篇 |
2001年 | 111篇 |
2000年 | 85篇 |
1999年 | 114篇 |
1998年 | 57篇 |
1997年 | 39篇 |
1996年 | 33篇 |
1995年 | 31篇 |
1994年 | 25篇 |
1993年 | 29篇 |
1992年 | 51篇 |
1991年 | 48篇 |
1990年 | 39篇 |
1989年 | 35篇 |
1988年 | 21篇 |
1987年 | 17篇 |
1986年 | 21篇 |
1985年 | 22篇 |
1984年 | 13篇 |
1983年 | 19篇 |
1982年 | 12篇 |
1980年 | 10篇 |
1979年 | 23篇 |
1978年 | 13篇 |
1972年 | 14篇 |
1971年 | 10篇 |
1969年 | 12篇 |
1966年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Jose M. Fernández-Cebrián Peter Vorwald Kuborn Mar Pardo de Lama Alfonso Sanjuanbenito Dehesa Manuel Nevado Santos Pedro A. Pacheco Martínez Beatriz Fernández-Escudero 《Clinical & translational oncology》2005,7(3):101-109
Colorectal cancer is one of the best studied of all malignant diseases interms of genetics and/or molecular prognostic factors. These factors, and relationships with prognosis, may have important implications especially in the design of surgical and adjuvant chemo-radiotherapy options. However, the true prognostic significance of all known factors has yet to be realised. We have reviewed the literature with specific focus on the role of molecular markers involved in prognosis and the prediction of response to adjuvant treatment. 相似文献
2.
3.
4.
5.
6.
María de Oña Navarro Santiago Melón Susana Méndez Beatriz Iglesias Ana Palacio María J. Bernardo José L. Rodriguez-Lambert Ernesto Gómez 《Transplant international》2002,15(11):570-573
Ganciclovir (GCV) prophylaxis or pre-emptive therapy significantly reduce the rate of cytomegalovirus (CMV) disease and viremia, but increase the potential for emergence of ganciclovir-resistant CMV strains. The inhibitor concentration at 50% (IC(50)) of GCV from 156 CMV isolates from 59 renal or heart transplant recipients was calculated by means of a rapid phenotypic susceptibility assay. Twenty-seven strains were from 14 patients undergoing GCV therapy. The IC(50) was higher in patients under the prophylaxis regimen. One CMV strain, from a heart transplant recipient, became GCV-resistant after 1 month of therapy (IC(50)=13.7 micromol/l). These data, together with clinical and virological markers, suggested that a switch to foscarnet was necessary, and good evolution was observed. Thus, assay of CMV susceptibility to GCV could be helpful in clinical management. 相似文献
7.
Doz. Dr. W. Klepetko T. Wekerle A. Moritz P. Mares M. Hiesmayer E. Tschernko I. Lang M. Kontrus W. Wisser E. Wolner 《European Surgery》1995,27(3):166-170
Zusammenfassung Grundlagen
Die pulmonale Thrombendarterektomie stellt eine effektive Therapie zur Behandlung von Patienten mit chronisch thromboembolischer
pulmonalar Hypertonie dar. Wir berichten über unsere Erfahrungen mit dieser Operationstechnik bei den ersten 9 Patienten.
Methodik
Zwischen 1992 und Oktober 1994 wurde bei 9 Patienten eine pulmonale Thrombendarterektomie durchgeführt. über eine mediane
Sternotomie wurden die Pulmonalarterien beider Seiten bis in ihre subsegmentalen Aufzweigungen im Sinne einer echten Endarterektomie
vom organisierten thromboembolischen Material befreit. Zumeist waren Perioden des totalen Kreislaufstillstandes in tiefer
Hypothermie notwendig, wobei diese zunehmend verkürzt werden konnten und 3 Patienten vollst?ndig ohne Kreislaufstopp operiert
wurden.
Ergebnisse
Die perioperative Mortalit?t betrug 11%, wobei der 1. Patient am 14. postoperativen Tag an den Folgen eines Reperfusions?dems
verstarb. Alle anderen Patienten sind 4 bis 22 Monate (im Mittel 13 Monate) nach dem Eingriff am Leben und zeigen eine Hochsignifikante
Verbesserung ihrer h?modynamischen Situation (mean PAP pr?operativ: 62 mm Hg, postoperativ: 30 mm Hg p<0,001; Cardiac Index
pr?operativ: 2,1 1/min/m2, postoperativ: 3,6 l/min/m2 p=0,001). W?hrend pr?operativ alle Patienten in NYHA-Klasse III oder IV waren, sind die 8 überlebenden jetzt alle in Klasse
I oder II.
Schlu?folgerungen
Die pulmonale Thrombendarterektomie bietet eine erfolgreiche Therapiem?glichkeit für Patienten mit chronisch thromboembolischer
pulmonaler Hypertonie mit einer in Anbetracht fehlender konservativer Altermativen akzeptablen Mortalit?t und ausgezeichneten
funktionellen Langzeitergebnissen.
相似文献
8.
Rui T Marinho Ruth M Pinto Maria L Santos Miguel Carneiro de Moura 《Liver international》2004,24(5):413-418
BACKGROUND: Seroreversion, negativation of anti-hepatitis C virus previously positive, is sometimes found in some chronic hepatitis C-sustained responders (SRs) to antiviral therapy. AIMS: To determine the probability of seroreversion in SR treatment with Interferon and Ribavirin, and lymphocyte T helper (CD4+) reactivity to HCV antigens. METHODS: Thirty SR were followed on average for 54.8 months. Anti-HCV was tested by third generation test. Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood and cultured to evaluate CD4+ proliferation in response to 2 microg/ml of eight HCV recombinant antigens from core, NS3, NS4, NS5 regions. RESULTS: Seroreversion was verified in 23% of patients (7/30), appearing at 47.5+/-24.0 months. The probability of anti-HCV loss in this group was 25% at 56 months after ending therapy. In 57% (4/7), anti-HCV returned to positive. These 7 SR patients with seroreversion also showed weaker CD4+ reactivity in 5% of tests (3/56) than the remaining 23 anti-HCV-positive SRs who showed stronger reactivity in 18% of tests (33/184), P=0.036. CONCLUSIONS: One-quarter of the SR showed seroreversion of anti-HCV and weaker CD4+ specific HCV proliferation than those who remained anti-HCV positive. The data suggest that complete viral eradication is a possible and achievable clinical objective. 相似文献
9.
Antonio Vaz Carneiro 《Revista portuguesa de cardiologia》2004,23(12):1633-1638
The rationale behind screening for asymptomatic coronary artery disease is that it may diagnose advanced disease that, while frequently without symptoms, may present for the first time as sudden death. Identifying significant coronary artery disease would enable intervention against risk factors and, if necessary, preventive revascularization. The most recent evidence shows that screening for coronary artery disease with resting electrocardiogram, exercise tolerance testing or electron-beam computerized tomography in low-risk patients does more harm than good, and should not be performed. This negative recommendation is based on the fact that the use of the aforementioned tests has a negative benefit-harm ratio, because the false-positive rate cancels out any benefit from the occasional detection of real disease, inducing a cascade of further testing (sometimes with angiography) and overdiagnosis of a disease that is not in fact present, with negative psychological and financial consequences, such as increased insurance premiums. We feel that the Portuguese Society of Cardiology should intervene with the institutions performing screening of coronary heart disease in asymptomatic patients, and recommend abandoning a practice that is of little use and, overall, harmful. 相似文献
10.
Harald Schrem Moritz Kleine Jürgen Borlak Jürgen Klempnauer 《Liver transplantation》2006,12(12):1832-1840
In fulminant hepatic failure, the use of bioartificial liver support (BAL) with porcine hepatocytes is the subject of a current and controversial debate.1 Specifically, the issue of cross-species physiological incompatibilities has not been addressed so far. We therefore investigated the effects of species-specific cytokines in single and cocultures on hepatocyte function. Hepatocyte cultures were isolated from human resection specimens and from Landrace pigs. Single and cocultures were exposed to porcine and human interleukin (IL)-6 or tumor necrosis factor (TNF)-alpha. Changes in expression of C-reactive protein (CRP), albumin, CCAAT enhancer binding protein (C/EBP)-alpha and C/EBP-beta and metabolic competence of cultured cells was studied by measuring testosterone metabolite production. After human or porcine IL-6 dosing, CRP was induced up to 100-fold in human hepatocyte cultures, while porcine hepatocytes responded marginally (2- to 5-fold). Treatment with human or porcine IL-6 or TNF-alpha resulted in reduced albumin production, albeit at different levels when human and porcine hepatocytes were compared (P = 0.001). Unlike human, porcine hepatocytes produced less of 6alpha-hydroxytestosterone (6alpha-HT) (P < 0.001) and 7alpha-HT (P < 0.001) after human or porcine IL-6 dosing and treatment with species-specific TNF-alpha induced (human hepatocytes) or decreased (porcine hepatocytes) 6beta-HT production (P = 0.021). In coculture with free exchange of metabolites, porcine hepatocytes produced less 6alpha-HT (P = 0.048) and 16alpha-HT (P = 0.033), whereas after treatment with human IL-6 reduced CRP gene and protein expression was observed with human hepatocytes (P = 0.013). In conclusion, species-specific responses of hepatocytes to cytokines and interactions with xenobiotic metabolites may limit the clinical effectiveness of porcine hepatocytes in BAL. 相似文献